Search results
Jazz Pharmaceuticals Trial for Suvecaltamide in Essential Tremor Misses Primary Endpoint
Market Watch· 4 days agoPublished: June 20, 2024 at 8:15 a.m. ETShareResizeBy Chris WackAbout Dow Jones NewswiresDow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional ...
Jazz Pharmaceuticals’ essential tremor drug falls flat in Phase IIb trial
Clinical Trials Arena via Yahoo Finance· 3 days agoJazz Pharmaceuticals’ suvecaltamide has failed to meet primary or key secondary endpoints in a Phase...
Essential tremor not linked to neurological disease
Jeffersonian Democrat· 3 days agoDear Doctors: I think I’m coming down with essential tremors, which run in my family. Dear Reader: When someone experiences shaking, trembling or other ...
Jazz Dives — But Key Rival Praxis Surges — On Essential Tremor Drug Failure
Investor's Business Daily· 3 days agoJazz stock toppled Thursday — while shares of rival Praxis Precision Medicines surged — after its ...
Jazz Pharmaceuticals' tremor drug fails in mid-stage study
Reuters via Yahoo News· 4 days agoThe drug, called suvecaltamide, was being tested in adults with essential tremor, a condition that affects the nervous system and causes involuntary and ...
Jazz hits dud note as midphase essential tremor test misses endpoint
FierceBiotech· 4 days agoJazz Pharmaceuticals hit a bum note Thursday, reporting the failure of a phase 2b essential tremor...
Diagnosing essential tremor after death helps fami | Newswise
Newswise· 6 days agoDALLAS – June 18, 2024 – A statistical tool designed to analyze 11 characteristics of postmortem...
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
BioPharma Dive via Yahoo Finance· 3 days agoA medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two...
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
Zacks via Yahoo Finance· 3 days agoJAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key...
Guggenheim Initiates Coverage on Praxis Precision Medicines (NASDAQ:PRAX)
ETF DAILY NEWS· 5 days agoGuggenheim started coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a report released on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating ...